Cover Image
市場調查報告書

Genentech, Inc.的產品平台分析

Genentech, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 253701
出版日期 內容資訊 英文 128 Pages
訂單完成後即時交付
價格
Back to Top
Genentech, Inc.的產品平台分析 Genentech, Inc. - Product Pipeline Review - 2016
出版日期: 2016年02月24日 內容資訊: 英文 128 Pages
簡介

Genentech, Inc.是總公司在美國的全球性的生物科技企業,進行生物醫藥品的研究、開發、製造、行銷等。以癌症,代謝性疾病,免疫性疾病,感染疾病,神經科學等為中心進行研究活動,其中著重於癌症、免疫性疾病、血管新生障礙領域的未滿足需求的醫藥品開發。

本報告提供Genentech, Inc. 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Genentech, Inc. 的基本資料

  • Genentech, Inc. 概要
  • 主要資訊
  • 企業資料

Genentech, Inc. :R&D概要

  • 主要的治療範圍

Genentech, Inc. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
  • 轉出授權產品

Genentech, Inc. :開發中產品概況

  • 後期階段產品開發中產品
  • 在臨床階段的開發中產品
  • 初期階段的開發中產品

Genentech, Inc. :藥物簡介

  • etrolizumab
  • lampalizumab
  • taselisib
  • crenezumab
  • duligotuzumab
  • ipatasertib
  • lifastuzumab vedotin
  • pictilisib
  • polatuzumab vedotin
  • quilizumab
  • RG-6046
  • RG-7652
  • RG-7745
  • DLYE-5953A
  • DMUC-4064A
  • RG-6047
  • RG-7450
  • RG-7741
  • RG-7841
  • RG-7842
  • RG-7882
  • RG-7888
  • RG-7893
  • BV-6
  • CS-3
  • G007-LK
  • G244-LM
  • GNE-293
  • GNE-317
  • GNE-3511
  • GNE-7915
  • GNE-892
  • MAb-30D8
  • Monoclonal Antibody Conjugate for Cancer
  • Monoclonal Antibody to Inhibit Tau for Alzheimer's Disease
  • MV-1
  • Small Molecule to Inhibit BACE1 for Alzheimer's Disease
  • Small Molecule to Inhibit MAP4K4 for Cancer
  • Small Molecule to Inhibit PI3K for Cancer
  • Small Molecule to Inhibit TYK2 for Psoriasis and IBD
  • Small Molecules to Inhibit JAK2 for Cancer
  • Small Molecules to Inhibit JAK2 for Myeloproliferative Neoplasms
  • Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma
  • Small Molecules to Inhibit Mammalian Rapamycin Kinase for Prostate Cancer
  • Small Molecules to Inhibit NAMPT for Cancer
  • Small Molecules to Inhibit PI3-Kinase Delta for Inflammatory and Leukocyte Disorders
  • Monoclonal Antibody Conjugated for Cancer
  • Small Molecule 2 for Undisclosed Indication
  • Small Molecule to Inhibit ITK for Allergic Asthma
  • Small Molecules 1 for Undisclosed Indication
  • Small Molecules for Bacterial Infections
  • Small Molecules for Central Nervous System Disorders
  • Small Molecules for Undisclosed Indication
  • Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation
  • Small Molecules to Inhibit Jak1/2 for Hematopoietic and Immunologic diseases
  • Small molecules to Inhibit Pim Kinase for Multiple Myeloma

Genentech, Inc. :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Genentech, Inc. :最近的開發平台資訊

Genentech, Inc. :開發休止的計劃

Genentech, Inc. :開發中止的開發中產品

  • 開發中止的開發中產品簡介

Genentech, Inc. :企業理念

Genentech, Inc. :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

Genentech, Inc. :主要的製造設施

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07958CDB

Summary

Global Markets Direct's, 'Genentech, Inc. - Product Pipeline Review - 2016', provides an overview of the Genentech, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Genentech, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Genentech, Inc.
  • The report provides overview of Genentech, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Genentech, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Genentech, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Genentech, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Genentech, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Genentech, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Genentech, Inc. Snapshot
    • Genentech, Inc. Overview
    • Key Information
    • Key Facts
  • Genentech, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Genentech, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • Genentech, Inc. - Pipeline Products Glance
  • Genentech, Inc. - Late Stage Pipeline Products
  • Genentech, Inc. - Clinical Stage Pipeline Products
  • Genentech, Inc. - Early Stage Pipeline Products
  • Genentech, Inc. - Drug Profiles
    • crenezumab
    • etrolizumab
    • lampalizumab
    • taselisib
    • duligotuzumab
    • ipatasertib
    • polatuzumab vedotin
    • quilizumab
    • RG-6046
    • RG-7745
    • BFKB-8488A
    • BTCT-4465A
    • DMUC-4064A
    • Drug for Inflammatory Diseases
    • DSTA-4637S
    • GDC-0134
    • GDC-0927
    • lifastuzumab vedotin
    • RG-6024
    • RG-6029
    • RG-7741
    • RG-7828
    • RG-7842
    • RG-7845
    • RG-7882
    • RG-7888
    • RG-7893
    • CS-3
    • G-007LK
    • G-244LM
    • GNE-293
    • GNE-317
    • GNE-3511
    • GNE-555
    • GNE-7915
    • GNE-892
    • MAb-30D8
    • Monoclonal Antibodies to Target CD98hc and BACE for Alzheimer's Disease
    • Monoclonal Antibody Conjugate for B-Cell Non Hodgkin's Lymphoma
    • Monoclonal Antibody Conjugates for Oncology
    • Monoclonal Antibody to Inhibit HtrA1 for Age Related Macular Degeneration
    • Monoclonal Antibody to Inhibit Tau for Alzheimer's Disease and Neurodegenerative Disorders
    • MV-1
    • pictilisib
    • Small Molecule to Inhibit BACE1 for Alzheimer's Disease
    • Small Molecule to Inhibit MAP4K4 for Cancer
    • Small Molecule to Inhibit TYK2 for Psoriasis and IBD
    • Small Molecules to Inhibit IRAK4 for Immunology and Oncology
    • Small Molecules to Inhibit JAK2 for Cancer
    • Small Molecules to Inhibit JAK2 for Myeloproliferative Neoplasms
    • Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma
    • Small Molecules to Inhibit NAMPT for Cancer
    • Small Molecules to Inhibit PI3-Kinase Delta for Inflammatory and Leukocyte Disorders
    • Monoclonal Antibody Conjugated for Cancer
    • Small Molecule 2 for Undisclosed Indication
    • Small Molecule to Inhibit ITK for Asthma
    • Small Molecules 1 for Undisclosed Indication
    • Small Molecules for Central Nervous System Disorders
    • Small Molecules for Undisclosed Indication
    • Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation
    • Small Molecules to Inhibit EGFR for Non-Small Cell Lung Cancer
    • Small Molecules to Inhibit Jak1/2 for Hematopoietic and Immunologic diseases
    • Small Molecules to Inhibit Ubiquitin Specific Protease for Oncology
  • Genentech, Inc. - Pipeline Analysis
    • Genentech, Inc. - Pipeline Products by Target
    • Genentech, Inc. - Pipeline Products by Route of Administration
    • Genentech, Inc. - Pipeline Products by Molecule Type
    • Genentech, Inc. - Pipeline Products by Mechanism of Action
  • Genentech, Inc. - Recent Pipeline Updates
  • Genentech, Inc. - Dormant Projects
  • Genentech, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • Genentech, Inc. - Company Statement
  • Genentech, Inc. - Locations and Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Genentech, Inc. - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Genentech, Inc., Key Information
  • Genentech, Inc., Key Facts
  • Genentech, Inc. - Pipeline by Indication, 2016
  • Genentech, Inc. - Pipeline by Stage of Development, 2016
  • Genentech, Inc. - Monotherapy Products in Pipeline, 2016
  • Genentech, Inc. - Partnered Products in Pipeline, 2016
  • Genentech, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Genentech, Inc. - Out-Licensed Products in Pipeline, 2016
  • Genentech, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Genentech, Inc. - Phase III, 2016
  • Genentech, Inc. - Phase II, 2016
  • Genentech, Inc. - Phase I, 2016
  • Genentech, Inc. - Preclinical, 2016
  • Genentech, Inc. - Discovery, 2016
  • Genentech, Inc. - Pipeline by Target, 2016
  • Genentech, Inc. - Pipeline by Route of Administration, 2016
  • Genentech, Inc. - Pipeline by Molecule Type, 2016
  • Genentech, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Genentech, Inc. - Recent Pipeline Updates, 2016
  • Genentech, Inc. - Dormant Developmental Projects,2016
  • Genentech, Inc. - Discontinued Pipeline Products, 2016
  • Genentech, Inc., Other Locations
  • Genentech, Inc., Key Manufacturing Facilities

List of Figures

  • Genentech, Inc. - Pipeline by Top 10 Indication, 2016
  • Genentech, Inc. - Pipeline by Stage of Development, 2016
  • Genentech, Inc. - Monotherapy Products in Pipeline, 2016
  • Genentech, Inc. - Partnered Products in Pipeline, 2016
  • Genentech, Inc. - Out-Licensed Products in Pipeline, 2016
  • Genentech, Inc. - Pipeline by Top 10 Target, 2016
  • Genentech, Inc. - Pipeline by Route of Administration, 2016
  • Genentech, Inc. - Pipeline by Molecule Type, 2016
  • Genentech, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top